

Prof. Dr. rer. nat. Christine Sers

Publications 2015 - 2017

2017

Thobe K, Sers C, Siebert H. Unraveling the regulation of mTORC2 using logical modeling. *Cell Commun Signal*. 2017 Jan 19;15(1):6. doi: 10.1186/s12964-016-0159-5

Mamlouk, S., Childs, L.H., Aust, D., Melching, F., Wolf, T., Oliveira, C., Durek, P., Schumacher, D., Bläker, H., von Winterfeld, M., Schäfer, R., Klauschen, F., Gastl, B., Heim, D., Möhr, K., Menne, A., Redmer, T., Lenze, D., Tierling, S., Morkel, M., Möbs, M., Weichert, W., Folprecht, G., Leser, U., and Sers, C. (2017). DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer. *Nat Commun*. 2017 Jan 25;8:14093. doi: 10.1038/ncomms14093

Riemer P, Rydenfelt M, Marks M, van Eunen K, Thedieck K, Herrmann BG, Blüthgen N, Sers C, Morkel M. Oncogenic β -catenin and PIK3CA instruct network states and cancer phenotypes in intestinal organoids. *J Cell Biol*. 2017 Jun 5;216(6):1567-1577. doi: 10.1083/jcb.201610058. Epub 2017 Apr 25.

Otto R, Sers C, Leser U. Robust in-silico identification of cancer cell lines based on next generation sequencing. *Oncotarget*. 2017 May 23;8(21):34310-34320. doi: 10.18632/oncotarget.16110

2016

Roßner F, Gieseler C, Morkel M, Royer HD, Rivera M, Bläker H, Dietel M, Schäfer R, Sers C. Uncoupling of EGFR-RAS signaling and nuclear localization of YBX1 in colorectal cancer. *Oncogenesis*. 2016 Jan 18;5:e187. doi: 10.1038/oncsis.2015.51

Fritsche-Guenther R, Witzel F, Kempa S, Brummer T, Sers C, Blüthgen N. Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis. *Oncotarget*. 2016 Feb 16;7(7):7960-9. doi: 10.18632/oncotarget.6959

Childs LH, Mamlouk S, Brandt J, Sers C, Leser U. SoFIA: a data integration framework for annotating high-throughput datasets. *Bioinformatics*. 2016 May 13. pii: btw302.

Möller Y, Morkel M, Schmid J, Beyes S, Hendrick J, Strotbek M, Riemer P, Schmid S, Schmitt LC, Kontermann R, Mürdter T, Schwab M, Sers C, Olayioye MA. Oncogenic Ras triggers hyperproliferation and impairs polarized colonic morphogenesis by autocrine ErbB3 signaling. *Oncotarget*. 2016 Jul 18. doi: 10.18632/oncotarget.10658.

Pavel ME, Sers C. WOMEN IN CANCER THEMATIC REVIEW: Systemic therapies in neuroendocrine tumors and novel approaches toward personalized medicine. *Endocr Relat Cancer*. 2016 Nov;23(11):T135-T154. Epub 2016 Sep 20. Review.

2015

Jurmeister P, Lenze D, Berg E, Mende S, Schäper F, Kellner U, Herbst H, Sers C, Budczies J, Dietel M, Hummel M, von Laffert M. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing. *Lung Cancer*. 2015 Feb;87(2):122-9.

Jesinghaus M, Wolf T, Pfarr N, Muckenhuber A, Ahadova A, Warth A, Goepfert B, Sers C, Kloor M, Endris V, Stenzinger A, Weichert W. Distinctive Spatiotemporal Stability of Somatic Mutations in Metastasized Microsatellite-stable Colorectal Cancer. *Am J Surg Pathol*. 2015 Mar 16.

Riemer P, Sreekumar A, Reinke S, Rad R, Schäfer R, Sers C, Bläker H, Herrmann BG, Morkel M. Transgenic expression of oncogenic BRAF induces loss of stem cells in the mouse intestine, which is antagonized by β -catenin activity. *Oncogene*. 2015 Jun 11;34(24):3164-75. doi: 10.1038/onc.2014.247. Epub 2014 Aug 11.

Dietel M, Jöhrens K, Laffert MV, Hummel M, Bläker H, Pfitzner BM, Lehmann A, Denkert C, Darb-Esfahani S, Lenze D, Heppner FL, Koch A, Sers C, Klauschen F, Anagnostopoulos I. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. *Cancer Gene Ther*. 2015 Sep;22(9):417-30. doi: 10.1038/cgt.2015.39. Epub 2015 Sep 11. Review

Morkel M, Riemer P, Bläker H, Sers C. Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. *Oncotarget*. 2015 Aug 28;6(25):20785-800. Review.